Trulieve Successfully Lists on NYSE, Marking Industry Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: NASDAQ.COM
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRLV
Wall Street analysts forecast TRLV stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 9.120
Low
Averages
High
Current: 9.120
Low
Averages
High
No data
About TRLV
Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Each of its three regional hubs is anchored by market positions in the cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require expertise in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including supercritical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, it utilizes distillation, purification, and manufacturing technologies to further refine extracts and transform them into a wide variety of finished products. Its brands include premium-tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trulieve Becomes First U.S. Cannabis Stock Listed on NYSE
- Historic Listing: Trulieve has become the first U.S. cannabis company to list on the New York Stock Exchange, marking a significant shift for an industry that has long been confined to Canadian exchanges and OTC markets, although the listing itself does not guarantee stock price increases.
- Strong Financial Performance: The company reported a GAAP gross profit of $170 million and a gross margin of 59% in its most recent quarter, demonstrating its ability to generate profit and meaningful free cash flow since 2021, highlighting its robust financial position in a competitive market.
- Improved Market Access: With Trulieve's NYSE listing, barriers for institutional investors, pension funds, and wealth managers have been removed, which is expected to enhance liquidity, analyst coverage, and institutional participation over time, despite the significant challenges still facing the industry.
- Valuation and Growth Challenges: Although Trulieve's market value is approximately $2.2 billion and trades at multiples below industry averages, revenue growth has slowed and price compression remains an issue, leading investors to maintain a cautious outlook on the industry's long-term prospects.
See More
Trulieve Achieves Historic NYSE Listing as First U.S. Cannabis Operator
- Historic Listing: Trulieve has become the first U.S. plant-touching cannabis company to list on the New York Stock Exchange, marking a significant breakthrough for an industry that has largely been confined to Canadian exchanges and OTC markets, although this milestone does not imply an immediate buy recommendation.
- Strong Profitability: Since 2021, Trulieve has consistently generated profits, reporting a GAAP gross profit of $170 million and a gross margin of 59% in its most recent quarter, along with $42 million in free cash flow, demonstrating robust performance in a competitive market.
- Solid Market Position: Operating 240 retail dispensaries and over 4 million square feet of cultivation and processing capacity, Trulieve is one of the largest cannabis retailers in the U.S., despite facing challenges such as price compression and regulatory uncertainty.
- Institutional Investment Opportunity: The NYSE listing is expected to attract more institutional investors, improving liquidity and analyst coverage, although the market remains cautious about the industry's long-term prospects, with a market value of approximately $2.2 billion and trading multiples indicating investor skepticism.
See More
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
Trulieve's NYSE Listing Marks Milestone for Marijuana Industry
- Industry Milestone: Trulieve Cannabis's listing on the NYSE as the first U.S.-based marijuana company to trade on a major exchange signifies a major advancement for the industry, likely attracting increased investor interest in the sector.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating robust growth potential in the medical marijuana sector and solidifying its market leadership.
- Market Opportunities: With projections indicating that the U.S. marijuana market could reach $76 billion by 2030, averaging an 11.5% annual growth rate, Trulieve is well-positioned to capitalize on significant expansion opportunities in both medical and recreational marijuana markets.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve's stock has risen 12% this year, and its strong financials and dominant market position make it an attractive option for long-term investors, particularly those willing to embrace the risks associated with marijuana stocks.
See More
Trulieve Successfully Lists on NYSE, Marking Industry Milestone
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
See More
Tilray Brands Faces Increased Competition Amid Market Changes
- Stock Decline: Tilray Brands' stock has plummeted 45% in 2026, indicating ongoing challenges in a competitive market, particularly after the legalization of cannabis in Canada led to increased competition and regulatory hurdles.
- Strategic Shift: In response to market pressures, Tilray has pivoted towards beverages and acquired craft brewers in an attempt to diversify its business and boost sales, yet this strategy has not significantly improved its financial performance.
- Increased Competition: The recent NYSE listing of Trulieve Cannabis allows investors easier access to the U.S. marijuana market, potentially diminishing interest in Tilray's stock and exacerbating its loss of market share.
- Financial Struggles: Tilray has reported operating losses for the past four quarters and has struggled to achieve consistent growth, leading to diminished investor confidence in its value, despite its seemingly low valuation.
See More
Trulieve Becomes First U.S. Cannabis Stock Listed on NYSE
- Historic Listing: Trulieve has become the first U.S. cannabis company to list on the New York Stock Exchange, marking a significant shift for an industry that has long been confined to Canadian exchanges and OTC markets, although the listing itself does not guarantee stock price increases.
- Strong Financial Performance: The company reported a GAAP gross profit of $170 million and a gross margin of 59% in its most recent quarter, demonstrating its ability to generate profit and meaningful free cash flow since 2021, highlighting its robust financial position in a competitive market.
- Improved Market Access: With Trulieve's NYSE listing, barriers for institutional investors, pension funds, and wealth managers have been removed, which is expected to enhance liquidity, analyst coverage, and institutional participation over time, despite the significant challenges still facing the industry.
- Valuation and Growth Challenges: Although Trulieve's market value is approximately $2.2 billion and trades at multiples below industry averages, revenue growth has slowed and price compression remains an issue, leading investors to maintain a cautious outlook on the industry's long-term prospects.
See More
Trulieve Achieves Historic NYSE Listing as First U.S. Cannabis Operator
- Historic Listing: Trulieve has become the first U.S. plant-touching cannabis company to list on the New York Stock Exchange, marking a significant breakthrough for an industry that has largely been confined to Canadian exchanges and OTC markets, although this milestone does not imply an immediate buy recommendation.
- Strong Profitability: Since 2021, Trulieve has consistently generated profits, reporting a GAAP gross profit of $170 million and a gross margin of 59% in its most recent quarter, along with $42 million in free cash flow, demonstrating robust performance in a competitive market.
- Solid Market Position: Operating 240 retail dispensaries and over 4 million square feet of cultivation and processing capacity, Trulieve is one of the largest cannabis retailers in the U.S., despite facing challenges such as price compression and regulatory uncertainty.
- Institutional Investment Opportunity: The NYSE listing is expected to attract more institutional investors, improving liquidity and analyst coverage, although the market remains cautious about the industry's long-term prospects, with a market value of approximately $2.2 billion and trading multiples indicating investor skepticism.
See More
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
Trulieve's NYSE Listing Marks Milestone for Marijuana Industry
- Industry Milestone: Trulieve Cannabis's listing on the NYSE as the first U.S.-based marijuana company to trade on a major exchange signifies a major advancement for the industry, likely attracting increased investor interest in the sector.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating robust growth potential in the medical marijuana sector and solidifying its market leadership.
- Market Opportunities: With projections indicating that the U.S. marijuana market could reach $76 billion by 2030, averaging an 11.5% annual growth rate, Trulieve is well-positioned to capitalize on significant expansion opportunities in both medical and recreational marijuana markets.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve's stock has risen 12% this year, and its strong financials and dominant market position make it an attractive option for long-term investors, particularly those willing to embrace the risks associated with marijuana stocks.
See More
Trulieve Successfully Lists on NYSE, Marking Industry Milestone
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
See More
Tilray Brands Faces Increased Competition Amid Market Changes
- Stock Decline: Tilray Brands' stock has plummeted 45% in 2026, indicating ongoing challenges in a competitive market, particularly after the legalization of cannabis in Canada led to increased competition and regulatory hurdles.
- Strategic Shift: In response to market pressures, Tilray has pivoted towards beverages and acquired craft brewers in an attempt to diversify its business and boost sales, yet this strategy has not significantly improved its financial performance.
- Increased Competition: The recent NYSE listing of Trulieve Cannabis allows investors easier access to the U.S. marijuana market, potentially diminishing interest in Tilray's stock and exacerbating its loss of market share.
- Financial Struggles: Tilray has reported operating losses for the past four quarters and has struggled to achieve consistent growth, leading to diminished investor confidence in its value, despite its seemingly low valuation.
See More
